FDA 授予 LBL-024 孤儿药资格认定，LBL-024 是一种抗 PD-L1/4-1BB ...

在过去的二十多年时间里，增强免疫系统对抗癌症的能力彻底改变了肿瘤的治疗格局，其中以靶向PD-1或PD-L1、CTLA-4为代表的免疫检查点抑制剂就是代表，目前靶向PD-1抗体类药物已经成为很多癌症的一线治疗方案，不过大多数情况下治疗应答率仅为15%到 ...

Io Therapeutics Inc. has presented new preclinical data on their RARγ agonist IRX-5010 for the treatment of triple-negative ...

（原标题：科伦药业：控股子公司抗PD-L1塔戈利单抗获批上市） 证券时报e公司讯，科伦药业(002422)1月1日晚间公告，公司控股子公司四川科伦博泰生物医药股份有限公司用于治疗既往接受过2线及以上化疗失败的复发或转移性鼻咽癌患者的靶向程序性细胞死亡配体1(PD-L1)的创新人源化单克隆抗体(简称“单抗”)塔戈利单抗(前称KL-A167)(科泰莱®)已获国家药监局批准于中国上市。

Adebrelimab is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Metastatic Pancreatic Cancer.

BeiGene (NASDAQ:BGNE) announced Friday that the U.S. Food and Drug Administration (FDA) approved its cancer medicine Tevimbra ...

JSKN033-102 is an open-label, multicenter, Phase Ⅰ/Ⅱ clinical study designed to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics and anti-tumor activity of JSKN033 in patients with ...

INR:2905. t20 world cup 2024 selection india team This 24-year-old medical professional became a billionaire overnight!

INR:6268. asia cup 2022 teams list CStone Pharmaceuticals' anti-PD-L1 study data in patients with esophageal squamous cell carcinoma are positive The ant ...